Prudentia Sciences is an AI-powered technology platform designed to accelerate investment in breakthrough therapies that change the world.

Prudentia’s AI-powered technology accelerates investment in breakthrough therapies by empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact. The platform enables investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking. It also equips investors with data-driven insights to optimize capital allocation in drug asset transactions.

Prudentia offers real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput. Its technology rapidly synthesizes datarooms into an asset assessment framework to determine asset risks and value drivers, and provides AI-guided product profiles and asset valuations to guide portfolio strategy and decision making.

The life sciences industry faces the challenge of scientific due diligence being manual, multidisciplinary, complex, resource intensive, and having a persistent disconnect between scientific potential, clinical reality, and financial valuation. Prudentia aims to address this challenge with its platform.

Prudentia Sciences acts as the operating system for life sciences deal-making, helping companies expand capacity and resources to review more deals, improve collaboration with experts, understand and maximize value drivers for assets, allocate capital efficiently, produce term sheets faster, and access industry experts and analytics at any time to evaluate investments.

The team consists of experienced professionals including the CEO & Founder Sadiqa Mahmood, CTO John Reynders, PhD, and several senior product designers, engineers, and scientific leads. The company also has a group of experts and advisors who bring diverse industry experience.